It became clear over the first quarter that the amount of business that had gone to the compounders was just significantly ...

Shares in Novo Nordisk were still up after Q1 2025 witnessed a total revenue jump by 18%, compared to Q1 2024.

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Novo Nordisk's (NVO) investors are worried its competition with ... Meanwhile, Novo has been busy forging deals with telehealth platforms, like Hims & Hers (HIMS), to increase access to Wegovy. Novo ...

Novo Nordisk (NVO) stock rises after Q1 2025 results, even after the company cut its outlook as it sees a sales recovery for ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

Hims & Hers Health (NYSE:HIMS) reported first-quarter earnings on Monday after the market closed and rocketed 18% after ...

Novo Nordisk reports its results in Danish kroner (DKK) rather than U.S. dollars. Sales grew 19% year over year to 78.1 ...

Hims & Hers (NYSE: HIMS) stock soared 18.2% in trading on Tuesday after the company reported first-quarter revenue growth of 111% and an increase in 2025 guidance. The results were phenomenal and a ...

While net income remains relatively thin, the business is scaling efficientlyand doing so across a growing number of ...

Express Scripts, Cigna, UnitedHealthcare, CVS Caremark and Optum Rx are among the payers that have added Yesintek to their ...